Initial preclinical investigation of aclarubicin treatment in primary cutaneous T-cell lymphoma cells

Fenna J de Bie, Morgann D Dettingmeijer, Sanne de Haan, Willem H Zoutman, Sabina Y van der Zanden, Cornelis P Tensen, Ferenc A Scheeren, Jacques Neefjes, Maarten H Vermeer · 2026

Read Initial preclinical investigation of aclarubicin treatment in primary cutaneous T-cell lymphoma cells by Fenna J de Bie, Morgann D Dettingmeijer, Sanne de Haan, Willem H Zoutman, Sabina Y van der Zanden, Cornelis P Tensen, Ferenc A Scheeren, Jacques Neefjes, Maarten H Vermeer (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13579395.txt.

Description

Fenna J de Bie and colleagues tested aclarubicin, a cancer drug, on cells taken from patients with skin T-cell lymphoma, a rare skin lymphoma. Old drugs in this class, such as doxorubicin, harm the heart and so have strict dose limits, while aclarubicin harms chromatin with no such build-up of heart harm. Tumour cells and normal CD4 T cells were both exposed to a set of these drugs in lab dishes.

With a brief two-hour dose that mimics blood levels in patients, aclarubicin killed tumour cells at far lower doses than the rest, with a half-kill dose eight to twenty times lower. It also did better when T cells were switched on. The drug merits more lab and clinic tests in this lymphoma.

Catalog record

CREATORFenna J de Bie, Morgann D Dettingmeijer, Sanne de Haan, Willem H Zoutman, Sabina Y van der Zanden, Cornelis P Tensen, Ferenc A Scheeren, Jacques Neefjes, Maarten H Vermeer
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE26 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13579395

Browse the full library · About the Tower of Babel